Ferring Pharmaceuticals, Inc.
400 Rella Boulevard
63 articles with Ferring Pharmaceuticals, Inc.
Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments
Collaboration brings together expertise from Ferring, Rebiotix and Karolinska Institutet to unlock the potential of the human microbiome
Ferring acquired exclusive U.S. commercialization rights for generic Ganirelix Acetate Injection for the prevention of premature ovulation in women undergoing fertility treatment
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
INVO Bioscience, Inc. and Ferring Pharmaceuticals announced today that the companies have entered into an exclusive U.S. commercialization rights agreement for INVOcell.
Ferring Pharmaceuticals Enters Exclusive Agreement with INVO Bioscience to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that it has signed an agreement to acquire from INVO Bioscience Inc. (OTCQB:IVOB) the exclusive U.S. commercialization rights for the INVOcell intravaginal culture (IVC) system, which comprises the INVOcell IVC device, retention device, and holding block.
NOCDURNA® (desmopressin acetate) Sublingual Tablets Now Available by Prescription in US for Treatment of Nocturia Due to Nocturnal Polyuria
NOCDURNA is the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities, effective December 31, 2018
REKOVELLE, the first recombinant follicle stimulating hormone derived from a human cell line, is now available for Canadian women undergoing IVF and other assisted reproductive technologies
REKOVELLE® helps women achieve a more predictable and targeted ovarian response
Ferring will access Evotec’s integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates
Rebiotix Clinical, Microbiome Data From First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
New data continues to underscore company leadership in microbiome field.
Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women’s Health
Research collaboration aims to uncover new insights into ovarian biology and accelerate the development of personalized interventions in reproductive medicine and women’s health.
From Menopausal Nuns to Israeli Biotech: Israel’s BTG Developed First Genetically Modified Hormon...
8/16/2018It’s been a while since FSH was manufactured using the urine of menopausal nuns. But now, an Israeli company, Bio-Technology General (BTG), owned by Italian company Ferring Pharmaceuticals, has developed a genetically-engineered version of FSH that can be personalized to improve the odds of a pat...
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
FDA Approves New Indications for ZOMACTON® (somatropin) as Ferring Plans Launch of Needle-Free Delivery System
Ferring Pharmaceuticals, Inc.. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications:
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
Male Fertility Survey Reveals 80 Percent of Men Feel Overlooked When Experiencing Infertility Challenges
Ferring Pharmaceuticals Inc. (US) has announced findings from a survey conducted with RESOLVE: The National Infertility Association to better understand how men feel when struggling with their own or their partner’s infertility.